College of Medicine, University of Suliamani
Sulaymaniyah, Kurdistan Region, 46001, Iraq
NCT Number: NCT06681116
We assessed the effect of structured nano-water in the prevention of recurrent stone formation in patients with recurrent calcium oxalate stones and hypercalciuria.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Sulaymaniyah, Kurdistan Region, 46001, Iraq
The majority of stones (85%) contain primarily calcium oxalate. Most renal stones are idiopathic calcium stones, and the most common predisposing factor in these patients is hypercalciuria. Structured nano-water is a new type of water that has been prepared using different types of energy fields electromagnetic fields to produce this structured nano- water that has new and different characteristics from the ordinary water.
In this study, we compared the efficacy of the nano- water with hydrochlorothiazide and with ordinary bottled drinking water in the prevention of recurrent renal stones in patients with idiopathic hypercalciuria.
We conducted a three-year randomized trial comparing the effect of structured water with the effect of hydrochlorothiazide and ordinary bottled water in 325 patients with recurrent calcium oxalate stones and hypercalciuria.
The patients were randomly divided into three groups. Group A included 108 patients who used structured nano-water in a dose of 20 mL/kg as a daily dose.
Group B of 107 patients used 50 mg hydrochlorothiazide tablets as a daily dose, and group C consisted of another 110 patients used ordinary drinking bottled water in a daily dose of 20 mL/kg .
The assessments were done by urine analysis with renal ultrasonography and radiology ( Kidney Ureter Bladder KUB X-rays) were done at baseline, at yearly intervals, also at any time of recurrence, and at the end of the 3 years (36th month).
The patients, care providers, and the investigators were blinded about the type of water used since the water bottles were unlabeled when given to the patients.
All patients were informed and signed a written informed consent form.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hydrochlorothiazide is a drug used to prevent recurrent renal stone formation in patients with idiopathic hypercalciuria
hydrochlorothiazide is a drug used to prevent recurrent stone formation i patients with idiopathic hypercalciuria
Patients with idiopathic hypercalciuria receiving regular bottled drinking water as a placebo to see its effect.
Time frame: From enrollment to the end of treatment at 36 months
recurrent renal stone were diagnosed by ultrasound and X-ray ( kidney ureter Bladder X-ray)
ALI KAMAL M. SAMI
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06615713
Calculi, Female Urogenital Diseases
Nadiād, India
View Trial DetailsNCT07522619
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Karachi, Sindh, Pakistan
View Trial DetailsNCT07464717
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Peshawar, KhyberPakhtunkhwa, Pakistan
View Trial DetailsNCT07360041
Calculi, Calculus
Cairo, Cairo Governorate, Egypt
View Trial Details